Antiplatelet Secondary Prevention International Randomised trial after INtracerebral haemorrhaGe (ASPIRING): a pragmatic, randomised, parallel group, open, phase 3, international superiority trial

脑出血后抗血小板二级预防国际随机试验 (ASPIRING)：一项务实、随机、平行组、开放、3 期国际优越性试验

• 批准号: 463680
• 负责人: Shoamanesh Ashkan
• 金额: $ 70.5万
• 依托单位: Population Health Research Institute (Hamilton, ON)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-03-01 至 2028-03-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=463680&lang=en
• 关键词: Antiplatelet Treatment; Antithrombotic Treatment; Hemorrhagic Stroke; Intracerebral Hemorrhage; Major Cardiovascular Events; Randomized Trial; Stroke

ASPIRING aims to improve the care of patients who survive stroke due to bleeding in the brain, known as "hemorrhagic stroke". Hemorrhagic strokes happen when weakened blood vessels rupture and cause bleeding in the brain. Patients with hemorrhagic stroke

ASPIRING旨在改善因脑出血（称为“出血性中风”）而存活的中风患者的护理。出血性中风发生时，脆弱的血管破裂，并导致出血的大脑。出血性中风患者